|
25 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
1 Trial |
|
217 News |
|
| 12345» |
- | acetylcysteine solution / Generic mfg.
Trial completion, Trial completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 30, 2019
P2, N=34, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Trial completion, Enrollment change, Metastases: Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC (clinicaltrials.gov) - Apr 20, 2019
P3, N=160, Completed, Sponsor: Fudan University
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 Recruiting --> Completed | N=320 --> 160
- | acetylcysteine solution / Generic mfg.
Enrollment change, Trial completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 19, 2019
P2, N=34, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | N=320 --> 160 N=18 --> 34 | Trial completion date: Dec 2018 --> May 2019
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 11, 2019
P2, N=9, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=18 --> 34 | Trial completion date: Dec 2018 --> May 2019 N=35 --> 9
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date: GORTEC-NPC2006: Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers (clinicaltrials.gov) - Jan 18, 2019
P3, N=83, Terminated, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
N=35 --> 9 Trial completion date: Dec 2017 --> Apr 2017 | Trial primary completion date: Dec 2017 --> Apr 2017
- | acetylcysteine solution / Generic mfg.
Phase classification: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Oct 31, 2018
P2, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Dec 2017 --> Apr 2017 | Trial primary completion date: Dec 2017 --> Apr 2017 Phase classification: P=N/A --> P2
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date: GORTEC-NPC2006: Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers (clinicaltrials.gov) - Aug 6, 2018
P3, N=83, Terminated, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Phase classification: P=N/A --> P2 Trial completion date: Aug 2015 --> Dec 2017 | Trial primary completion date: Aug 2015 --> Dec 2017
- | Trial completion: CRUKD/13/001: A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jul 17, 2018
P1, N=22, Completed, Sponsor: Cancer Research UK
Trial completion date: Aug 2015 --> Dec 2017 | Trial primary completion date: Aug 2015 --> Dec 2017 Active, not recruiting --> Completed
- | oxycodone controlled release / Generic mfg.
Trial completion, Phase classification: Early Use of Opioid in Radiation Mucositis (clinicaltrials.gov) - Jul 17, 2018
P2, N=200, Completed, Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Active, not recruiting --> Completed Not yet recruiting --> Completed | Phase classification: PN/A --> P2
- | Enrollment change: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jun 20, 2018
P=N/A, N=720, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Completed | Phase classification: PN/A --> P2 N=500 --> 720
- | cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 1, 2018
P1/2, N=3, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=500 --> 720 Active, not recruiting --> Completed
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion, Metastases: FMTN-I-LNPC: Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 18, 2018
P1, N=20, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Recruiting --> Completed
- |||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion, Metastases: Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Apr 18, 2018
P2, N=58, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed Recruiting --> Completed
- | acetylcysteine solution / Generic mfg.
Trial completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Trial completion date: Apr 2018 --> Dec 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Feb 26, 2018
P2, N=24, Completed, Sponsor: Fox Chase Cancer Center
Trial completion date: Apr 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017
- | Trial primary completion date: CRUKD/13/001: A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 6, 2018
P1, N=22, Active, not recruiting, Sponsor: Cancer Research UK
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017 Trial primary completion date: Mar 2017 --> Mar 2018
- | atorvastatin / Generic mfg.
Trial suspension: Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis (clinicaltrials.gov) - Dec 4, 2017
P2, N=324, Suspended, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Suspended
- | Onureg (azacitidine oral) / BMS
Trial completion, Metastases: Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Dec 2, 2017
P2, N=36, Completed, Sponsor: Celgene
Recruiting --> Suspended Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Aug 16, 2017
P2, N=33, Completed, Sponsor: Hong Kong Nasopharyngeal Cancer Study Group Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=500, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2019
- | atorvastatin / Generic mfg.
Trial initiation date: Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis (clinicaltrials.gov) - May 8, 2017
P2, N=324, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial primary completion date: Dec 2017 --> Dec 2019 Initiation date: Dec 2013 --> Jan 2017
- | Inlyta (axitinib) / Pfizer
Trial completion, Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Apr 25, 2017
P2, N=37, Completed, Sponsor: Chinese University of Hong Kong
Initiation date: Dec 2013 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016
- | Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 18, 2017
P1, N=28, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016 Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=10 --> 28 | Trial primary completion date: Jun 2017 --> Jun 2015
- Onureg (azacitidine oral) / BMS
Trial primary completion date, Metastases: Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 6, 2017
P2, N=36, Active, not recruiting, Sponsor: Celgene
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=10 --> 28 | Trial primary completion date: Jun 2017 --> Jun 2015 Trial primary completion date: Mar 2017 --> Jun 2017
- | Trial completion, Trial primary completion date, Metastases: New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=70, Completed, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Mar 2017
- | cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Mar 3, 2017
P1/2, N=3, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Feb 27, 2017
P2, N=33, Active, not recruiting, Sponsor: Hong Kong Nasopharyngeal Cancer Study Group Limited
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- Enrollment change: LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) (clinicaltrials.gov) - Feb 7, 2017
P1, N=23, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting N=29 --> 23
- Onureg (azacitidine oral) / BMS
Trial primary completion date, Metastases: Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 23, 2017
P2, N=36, Active, not recruiting, Sponsor: Celgene
N=29 --> 23 Trial primary completion date: Dec 2016 --> Mar 2017
- Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Jan 13, 2017
P2, N=37, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- MK-2206 / Merck (MSD)
Trial completion, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 13, 2017
P2, N=12, Completed, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- Aqupla (nedaplatin) / Simcere
Trial primary completion date, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 28, 2016
P3, N=402, Completed, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Trial primary completion date: Mar 2012 --> May 2014
- | Aqupla (nedaplatin) / Simcere
Trial completion, Trial primary completion date, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 18, 2016
P3, N=402, Completed, Sponsor: Sun Yat-sen University
Trial primary completion date: Mar 2012 --> May 2014 Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Mar 2012
- MK-2206 / Merck (MSD)
Enrollment change, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 30, 2016
P2, N=12, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Mar 2012 N=45 --> 12
- Enrollment closed, Metastases: New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=70, Active, not recruiting, Sponsor: Chinese University of Hong Kong
N=45 --> 12 Recruiting --> Active, not recruiting
- Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jul 29, 2016
P1/2, N=3, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2017 N=41 --> 3 | Trial primary completion date: Mar 2017 --> Dec 2016
- Onureg (azacitidine oral) / BMS
Trial primary completion date, Metastases: Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jul 20, 2016
P2, N=36, Active, not recruiting, Sponsor: Celgene Corporation
N=41 --> 3 | Trial primary completion date: Mar 2017 --> Dec 2016 Trial primary completion date: May 2016 --> Dec 2016
- Enrollment open, Trial primary completion date: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=500, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: May 2016 --> Dec 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2017
- Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2017 Trial primary completion date: Jan 2016 --> Jun 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=24, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Jan 2016 --> Jun 2016 Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015
- acetylcysteine solution / Generic mfg.
Enrollment closed, Enrollment change: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015 Recruiting --> Active, not recruiting | N=36 --> 18
- MK-2206 / Merck (MSD)
Trial primary completion date, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 30, 2016
P2, N=45, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Active, not recruiting | N=36 --> 18 Trial primary completion date: May 2015 --> Dec 2016
- Trial primary completion date, Metastases: New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer (clinicaltrials.gov) - Jan 30, 2016
P=N/A, N=68, Recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: May 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Inlyta (axitinib) / Pfizer
Enrollment closed, Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Jan 30, 2016
P2, N=37, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2016
- | Onureg (azacitidine oral) / BMS
Enrollment closed, Enrollment change, Metastases: Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Dec 25, 2015
P2, N=36, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2016 Recruiting --> Active, not recruiting | N=55 --> 36
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=55 --> 36 Active, not recruiting --> Completed
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Trial completion, Trial primary completion date, Metastases: Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 22, 2015
P2, N=39, Completed, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2015
- carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: CADEN: Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (clinicaltrials.gov) - Sep 9, 2015
P2, N=20, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2015 Active, not recruiting --> Completed | N=25 --> 20 | Trial primary completion date: Jan 2015 --> Jun 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Sep 8, 2015
P2, N=43, Recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed | N=25 --> 20 | Trial primary completion date: Jan 2015 --> Jun 2014 Trial primary completion date: Feb 2015 --> Feb 2016